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RESEARCH ARTICLE
PAIRUP-MS: Pathway analysis and imputation
to relate unknowns in profiles from mass
spectrometry-based metabolite data
Yu-Han H. HsuID1,2,3, Claire Churchhouse4,5, Tune H. Pers6,7, Josep M. MercaderID3,8,
Andres Metspalu9, Krista Fischer9,10, Kristen Fortney11, Eric K. Morgen11,
Clicerio GonzalezID12,13, Maria E. GonzalezID12,13, Tonu Esko3,9, Joel N. HirschhornID1,2,3*
1 Department of Genetics, Harvard Medical School, Boston, Massachusetts, United States of America,
2 Division of Endocrinology and Center for Basic and Translational Obesity Research, Boston Children’s
Hospital, Boston, Massachusetts, United States of America, 3 Programs in Metabolism and Medical &
Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, United States of
America, 4 Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge,
Massachusetts, United States of America, 5 Analytical and Translational Genomics Unit, Massachusetts
General Hospital, Boston, Massachusetts, United States of America, 6 Novo Nordisk Foundation Centre
for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark, 7 Department of
Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark, 8 Diabetes Unit and Center for
Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States of America,
9 Estonian Genome Center, Institute of Genomics, University of Tartu, Tartu, Estonia, 10 Institute of
Mathematics and Statistics, University of Tartu, Tartu, Estonia, 11 BioAge Labs, Richmond, CA, United
States of America, 12 Instituto Nacional de Salud Publica, Cuernavaca, Morelos, Mexico, 13 Centro de
Estudios en Diabetes, Mexico City, Mexico
* Joel.Hirschhorn@childrens.harvard.edu
Abstract
Metabolomics is a powerful approach for discovering biomarkers and for characterizing the
biochemical consequences of genetic variation. While untargeted metabolite profiling can
measure thousands of signals in a single experiment, many biologically meaningful signals
cannot be readily identified as known metabolites nor compared across datasets, making it
difficult to infer biology and to conduct well-powered meta-analyses across studies. To over-
come these challenges, we developed a suite of computational methods, PAIRUP-MS, to
match metabolite signals across mass spectrometry-based profiling datasets and to gener-
ate metabolic pathway annotations for these signals. To pair up signals measured in differ-
ent datasets, where retention times (RT) are often not comparable or even available, we
implemented an imputation-based approach that only requires mass-to-charge ratios (m/z).
As validation, we treated each shared known metabolite as an unmatched signal and
showed that PAIRUP-MS correctly matched 70–88% of these metabolites from among
thousands of signals, equaling or outperforming a standard m/z- and RT-based approach.
We performed further validation using genetic data: the most stringent set of matched sig-
nals and shared knowns showed comparable consistency of genetic associations across
datasets. Next, we developed a pathway reconstitution method to annotate unknown signals
using curated metabolic pathways containing known metabolites. We performed genetic
validation for the generated annotations, showing that annotated signals associated with
gene variants were more likely to be enriched for pathways functionally related to the genes
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Individual-level metabolite data for the OE cohort
and the signal-metabolite set annotation matrix
constructed from BioAge data are also available on
the GitHub. Due to Estonian Biobank’s regulations,
individual-level OE genetic data and BioAge data
need to be requested through an application to the
biobank (https://www.geenivaramu.ee/en/biobank.
ee/data-access). Other questions about OE and
compared to random expectation. Finally, we applied PAIRUP-MS to study associations
between metabolites and genetic variants or body mass index (BMI) across multiple data-
sets, identifying up to ~6 times more significant signals and many more BMI-associated
pathways compared to the standard practice of only analyzing known metabolites. These
results demonstrate that PAIRUP-MS enables analysis of unknown signals in a robust, bio-
logically meaningful manner and provides a path to more comprehensive, well-powered
studies of untargeted metabolomics data.
Author summary
Untargeted metabolomics can systematically profile thousands of metabolite signals in
biological samples and is an increasingly popular approach for discovering biomarkers
and predictors for human traits and diseases. However, currently, a significant portion of
the measured signals cannot be identified as known metabolites or easily compared across
datasets, and thus are usually excluded from downstream analyses. Here, we present
PAIRUP-MS, a suite of computational methods designed to analyze unknown, unidenti-
fied signals across multiple mass spectrometry-based profiling datasets. Specifically,
PAIRUP-MS contains a flexible imputation-based approach for pairing up unknown sig-
nals across datasets, allowing for meta-analysis of matched signals across studies that
would otherwise be incompatible. PAIRUP-MS also offers a pathway annotation and
enrichment analysis framework that links metabolite signals to plausible biological func-
tions without using their chemical identities. Importantly, we validated both components
of PAIRUP-MS using genetic data and applied them to study an example trait, body mass
index. Overall, our results demonstrate that PAIRUP-MS enables previously infeasible
analyses of unknown, unidentified signals across multiple datasets, thereby greatly
improving power for discovery and biological inference.
Introduction
Metabolomics is a powerful systematic approach for studying circulating molecules in biologi-
cal samples [1, 2]. Profiling technologies such as nuclear magnetic resonance (NMR) spectros-
copy and liquid or gas chromatography followed by mass spectrometry (LC-MS or GC-MS)
have been used to discover metabolites that are biomarkers or predictors for various human
traits and diseases, including clinical risk factors of metabolic or cardiovascular diseases [3],
type 2 diabetes [4], and all-cause mortality [5]. Genome-wide association studies (GWAS)
have also identified numerous metabolic quantitative trait loci (mQTLs) that influence varia-
tion in metabolite abundance, which may provide valuable insights into gene functions and
disease mechanisms [6–9].
While metabolomics has led to many new discoveries, a significant portion of the generated
data have not been used to its full potential. Untargeted profiling platforms collect measure-
ments for thousands of metabolite signals and compare their data to standards in compound
databases to identify known metabolites [1]. Current identification procedures can identify up
to a few hundred known metabolites and the remaining unknown signals are often excluded
from downstream analyses. However, studying unknown signals may be fruitful for several
reasons. First, many unknowns show correlation with known metabolites, phenotypes, and
genetic variants, indicating that they capture biological information [10]. Second, because
Analyzing unknown signals in mass spectrometry-based metabolite data
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unknowns usually make up a large portion of untargeted data, including them can greatly
increase the search space in analyses. Finally, investigating unknown signals may enable us to
discover novel biomarkers that have not been characterized in human metabolism. Therefore,
developing computational methods that deal with unknown signals is critical for making the
most out of untargeted metabolomics data.
Analyzing unknown signals poses several challenges. Distinguishing biological signals from
noise and adjusting for technical artifacts are difficult, because unknowns are often associated
with noisier measurements compared to known metabolites [11]. Meta-analysis, which may
increase power for detecting noisy but true signals, is complicated by the lack of gold standard
protocols and varying signal characteristics across platforms and studies. While some methods
have been developed to align signals across datasets using mass-to-charge ratio (m/z) and/or
retention time (RT) information, their applications are often restricted to processing data
batches within a single study or data generated by the same profiling method [11–13]. Another
main challenge is to link unknown signals to biological functions before confirming their
exact chemical identities. Although several pathway or network-based approaches have incor-
porated unknown signals into metabolomics analyses, they focus on a small subset of the
unknowns (e.g. those directly associated with known metabolites, genes, or a trait of interest)
and do not explicitly provide biological interpretations (e.g. pathway labels) for enriched path-
ways or network clusters identified during analysis [10, 14, 15].
To overcome the challenges described above, we developed and implemented a suite of
computational methods, PAIRUP-MS (Pathway Analysis and Imputation to Relate Unknowns
in Profiles from MS-based metabolite data), for analyzing unknown signals. PAIRUP-MS can
be applied to MS-based profiling datasets in which signal peaks have been detected, aligned,
and quantified, and where some peaks have been identified as known metabolites. PAIR-
UP-MS is used to further process, match, and annotate the unknown signals and to perform
meta-analysis and pathway-based analysis that include unknown signals. We utilized genetic
associations to validate the methods and demonstrated their application by studying metabo-
lite signals associated with body mass index (BMI). Our framework can be applied to diverse
untargeted profiling datasets produced by typical MS-based profiling platforms and will help
to advance metabolomics as a powerful approach for elucidating biology underlying human
traits and diseases.
Results
Metabolomics datasets and data processing
We developed and tested PAIRUP-MS using LC-MS profiling data generated from three inde-
pendent cohorts: (1) Obesity Extremes cohort (OE): 300 individuals (100 lean, 100 obese, and
100 population control) sampled from the Estonian Biobank, (2) Mexico City Diabetes Study
cohort (MCDS): 865 individuals in a prospective type 2 diabetes study, and (3) BioAge Labs
Mortality cohort (BioAge): 583 individuals selected from the Estonian Biobank for a retrospec-
tive mortality study. In order to reduce noise in the profiling data and to improve power in
analyses, we implemented a quality control (QC) pipeline to adjust each dataset for measure-
ment variation associated with technical artifacts and remove samples, metabolite signals, and
data points with noisy trends (S1 Fig). After QC, we leveraged the correlation structure among
signals to impute any remaining missing values within a dataset. In the end, the OE dataset
contained 298 samples and 13,613 metabolite signals (322 known and 13,291 unknown);
MCDS contained 821 samples and 7,136 signals (242 known and 6,894 unknown); BioAge
contained 583 samples and 14,617 signals (603 known and 14,014 unknown). Covariate adjust-
ment (if appropriate) and rank-based inverse normal transformation were performed on each
Analyzing unknown signals in mass spectrometry-based metabolite data
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metabolite signal and the resulting abundance z-scores were used in downstream analyses.
QC’ed cohort and dataset characteristics are summarized in Table 1. Known metabolites in
QC’ed datasets are listed in S1 Table.
Matching metabolite signals across datasets
Matching method overview. An approach for comparing unknown signals measured in
different untargeted profiling datasets is crucial for increasing power in metabolomics studies.
Instead of using RT information, which can vary greatly across profiling methods and plat-
forms, we developed a method that utilizes m/z and imputation to match up signals likely to
represent the same metabolites across MS-based profiling datasets (Fig 1A). In preliminary
analysis, we observed that known metabolites measured across our three datasets had moder-
ately similar correlation structures despite substantial differences in study populations and
designs (S2 Fig). We took advantage of this observation and imputed the abundance of
unknown (or unshared known) signals from one dataset to another using shared known
metabolites as predictors in linear regression models. The imputation then allowed us to calcu-
late the correlation between signals measured in different datasets across a common set of
samples and to pair up signals based on agreement in m/z and this correlation.
Calibration using shared known metabolites. In order to calibrate parameters in our
method, we treated known metabolites shared across two datasets as unmatched signals and
applied our method to match each of them in turn. We compared the performance of different
parameter settings by calculating the percentage of matches that were either the correct match
or highly correlated (r2 > 0.8) with the correct match in observed data. The parameter choices
we tested included: (1) whether to consider different adduct ions when checking for m/z agree-
ment, (2) which set of samples to use for calculating correlation between signals, (3) whether
to allow multiple-to-1 signal matching or require unique 1-to-1 matching, (4) whether to
match only signals measured by the same profiling method or allow matching across different
methods, and, optionally, (5) which correlation cutoff threshold to use for calling a match.
The calibration results for OE-MCDS, OE-BioAge, and MCDS-BioAge matching are
shown in S3–S5 Figs and the optimal parameter settings chosen for each dataset pair are
Table 1. Characteristics of study cohorts and corresponding metabolomics datasets.
Obesity Extremes cohort (OE) Mexico City Diabetes Study cohort
(MCDS)
BioAge Labs Mortality cohort
(BioAge)
Study design BMI extremes from Estonian Biobank
(EB)
Prospective cohort for type 2 diabetes Retrospective cohort for mortality from
EB
# of samples 298 821 583
# of women (%) 149 (50.0) 498 (60.7) 407 (69.8)
Age (yr) 38.5 ± 12.1 52.3 ± 7.73 73.3 ± 2.70
BMI (kg/m2) 28.3 ± 9.95 28.6 ± 4.54 27.3 ± 4.33
Fasting time� (hr) 7.42 ± 3.34 overnight 3.04 ± 2.80
Profiling methods�� C8-pos, C18-neg, HILIC-pos, HILIC-neg LIPID, HILIC-pos, CMH C8-pos, C18-neg, HILIC-pos, HILIC-neg
# of signals (# of knowns) 13,613 (322) 7,136 (242) 14,617 (603)
# of signals with m/z data (# of
knowns)
13,552 (261) 7,083 (189) 14,617 (603)
Mean ± standard deviation is reported for quantitative phenotypes.
� Fasting time for OE and BioAge was not exact due to conversion from categorical variable; 200 BioAge samples had no fasting time information.
�� Italicized profiling methods had m/z and RT information available; we treated "C8-pos" and "LIPID" to be the same method in our analyses due to large overlap in the
metabolites they measured; see S1 Text for profiling method details.
https://doi.org/10.1371/journal.pcbi.1006734.t001
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Fig 1. PAIRUP-MS is a suite of computational methods for analyzing metabolite signals in untargeted metabolomics data. (a) Overview of
matching method: unknown (or unshared known) signals are imputed across datasets using shared known metabolites as predictors and then paired
up based on m/z and correlation across samples. Genetic data can be used to validate matched signal pairs that share similar genetic associations.
Matched signals can be used to perform combined association analyses across datasets (e.g. identifying trait-associated signals in discovery and
replication cohorts). (b) Overview of pathway method: using binary metabolic pathway annotations and untargeted profiling data as input, a pathway
reconstitution procedure is performed to construct a numeric annotation matrix, where each signal (known or unknown) gets a membership score in
each pathway (or “metabolite set”, see Methods). Genetic data can be used to validate that signals associated with a specific gene are enriched for
reconstituted pathways related to the gene. The annotation matrix can be used to perform pathway analyses (e.g. identifying pathways enriched for a list
of trait-associated signals).
https://doi.org/10.1371/journal.pcbi.1006734.g001
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summarized in S2A Table. We decided to consider two types of matches, “multiple” and
“reciprocal”, for subsequent analyses. Briefly, in the “multiple” setting, we matched each Data-
set 1 signal, s, to a Dataset 2 signal by first identifying all Dataset 2 signals whose m/z agree
with s, and then selecting the one that has the best correlation with s to be the final match. Fol-
lowing this procedure, more than one Dataset 1 signal may be mapped to the same Dataset 2
signal. For “reciprocal” matches, we repeated the same procedure to match Dataset 1 signals to
Dataset 2 and vice versa, and only kept the subset of matches that were generated in both direc-
tions. Our method performed slightly better using the “reciprocal” setting, in which it correctly
paired up 69.9 to 87.6% of the matched knowns, with 91.6 to 96.4% of all matches showing
strong correlation (r2 > 0.8) with the correct match. However, the “multiple” setting also per-
formed relatively well (58.4 to 87.1% of matches were correct; 91.0 to 96.1% were highly corre-
lated) and identified more correct or highly correlated matches overall, so both match types
can be useful, depending on the analysis context.
We compared our method against a m/z and RT-based matching approach, where signals
with agreeing m/z were mapped to each other based on predicted RT calculated from shared
known metabolite data. The imputation method generally performed as well as or slightly better
than the RT method, despite not using any RT information (S2A Table). An important advan-
tage of the imputation approach is that, even when the matches made for known metabolites
were incorrect, ~60–80% of them were strongly correlated (r2 > 0.8) with the true known
matches. In contrast, incorrect matches made by the RT approach sometimes showed much
weaker correlation. These results suggest that our method can be used to discover “proxies” for
metabolites in a dataset even when an exact match does not exist or could not be identified. Fur-
thermore, when we allowed matching across profiling methods, the RT approach showed a big-
ger dip in performance compared to the imputation approach (S2B Table). Thus, imputation-
based matching may be a more flexible framework for comparing datasets generated by diverse
profiling platforms, especially when directly comparable RT data is not available.
Dataset characteristics such as sample size, number of shared known metabolites, and simi-
larity in metabolite correlation structure can influence performance of the imputation-based
matching approach. We ran additional analyses using random subsets of MCDS and BioAge
samples to assess matching performance across a range of sample sizes (S6A Fig). We observed
that the fraction of correct or highly correlated matched knowns tended to increase with sam-
ple size, stabilizing after each dataset contained at least ~300 samples. Similarly, when we per-
formed matching using subsets of MCDS-BioAge shared known metabolites as predictors
during imputation, performance improved as the number of shared knowns increased (S6B
Fig). Finally, to check how overall similarity in metabolite correlation structure influences
matching performance, we assessed OE-MCDS, OE-BioAge, and MCDS-BioAge similarities
by first calculating pairwise correlations between shared known metabolites within each data-
set and then calculating the correlation of these pairwise correlations across each pair of data-
sets (S2 Fig). We observed that the most similar dataset pair, MCDS-BioAge (r2 = 0.625), had
the best matching performance, while the least similar pair, OE-MCDS (r2 = 0.400), performed
the worst (S2A Table). Together, these results indicate that the imputation-based matching
procedure is more effective at matching larger datasets with more known metabolites and
composed of similar samples. Based on these analyses, we suggest that having ~300 samples
per dataset, ~200 shared known metabolites, and r2 > 0.4 in terms of metabolite correlation
similarity should be sufficient to achieve matching performance similar to what we describe in
this paper. However, empirical assessment of matching performance using shared knowns is
still recommended for new datasets.
Genetic validation of matched signals. After demonstrating that the matching method
could be used to accurately pair up shared known metabolites, we next sought to validate the
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full set of matches. Because there is no uniform “gold standard” for matching unknown sig-
nals, we used genetic data to validate matched signals between OE and MCDS, reasoning that
useful matches would have similar patterns of genetic association across the two cohorts. We
performed a GWAS in both OE and MCDS for the matched signal pairs (4,432 “multiple”
matches, 1,573 of which were “reciprocal”); we also analyzed an additional 207 pairs of shared
knowns and 20 sets of 4,432 randomly matched pairs to serve as positive and negative controls,
respectively. To assess how well we had selected matching pairs, we determined the overall
directional consistency of association for the best-associated single nucleotide polymorphisms
(SNPs) with the matched signal pairs. Specifically, for each matched pair, we identified the
SNP with the best p-value in a GWAS meta-analysis of OE and MCDS, and tested whether the
same allele was associated with increased metabolite levels across the two studies. (To avoid
biasing the subsequent assessment of directional consistency, we forced all SNPs to have the
same direction of effect when calculating meta-analysis p-values; see Methods).
For the 94 pairs of shared knowns that had genome-wide significant (p< 5 × 10−8) SNPs in
the meta-analysis, 66 pairs (70.2%; Fisher’s p = 1.56 × 10−4) showed directional consistency; in
comparison, 478 out of 672 (71.1%; Fisher’s p = 1.83 × 10−28) “reciprocal” or 1,119 out of 1,772
(63.1%; Fisher’s p = 3.08 × 10−28) “multiple” matched pairs were consistent, both of which were sig-
nificantly better than randomly matched signals (average consistency of 52.1%; empirical p< 0.05;
Fig 2A–2C). Importantly, at more stringent p-value thresholds, as many as 91.4% of the “recipro-
cal” matched pairs had directional consistency, compared to a ceiling of 90.3% for the shared
knowns, indicating that these matches for unknown signals show similar consistency as shared
known metabolites (Fig 2C). In addition, we estimated true positive rate for the matched signals
by assuming that true matches would show same degree of consistency as the shared knowns, and
found that the “multiple” setting generated more true positive matches overall (Fig 2D), albeit at a
lower confidence level (maximum true positive rate of 83.0%; Fig 2E). In summary, the most strin-
gent application of our method (“reciprocal” setting) identified ~7 times as many high-confidence
matches compared to the shared knowns. The method can also be used to generate many more
potential matches under more lenient settings (e.g. cross-method matching, S7 Fig).
Application to perform GWAS replication and meta-analysis. In order to directly assess
how much power we gained from matching metabolite signals, we also performed GWAS rep-
lication analysis using OE and MCDS as the discovery and replication cohorts, respectively.
Out of 14 shared knowns that had genome-wide significant associations in OE, 7 had nomi-
nally significant (p< 0.05) and directionally consistent associations in MCDS. In comparison,
156 “reciprocal” matched signal pairs had genome-wide significant hits in OE, 56 of which had
replicated associations in MCDS. Furthermore, after meta-analyzing the two cohorts (this
time taking direction of effect into account), we found 71 shared knowns and 512 matched sig-
nal pairs with genome-wide significant associations. Among the significant matched signal
pairs, 93 (18.2%) contained potentially redundant signals as the measured known metabolites:
48 pairs directly contained known metabolites; 45 pairs had m/z matching adduct masses of
the known metabolites recorded in the Human Metabolome Database (HMDB) [16]. How-
ever, the rest of the significant matched pairs (81.8%) may be capturing additional metabolites
not identified in our datasets: 225 had m/z matching adducts of unmeasured HMDB metabo-
lites and 194 had m/z values with no record in HMDB (which may be previously characterized
metabolites that have not been documented in HMDB, such as xenobiotics foreign to the
human body, or truly novel molecules that have yet to be characterized). Based on these num-
bers, we estimated that our method enabled the identification of ~6 times more metabolite sig-
nals with significant associations.
Application to identify BMI-associated signals. To further showcase the utility of signal
matching, we also applied our method to identify metabolite signals associated with BMI in
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OE and MCDS. First, we identified 1,474 signals (114 known and 1,360 unknown) that were
significantly (p< 0.05/13,613) associated with BMI in OE and tested for their replication in
MCDS. Out of the 96 BMI-associated OE known metabolites that were also measured in
MCDS, 75 (78.1%) showed directionally consistent association with BMI at a nominal signifi-
cance threshold in MCDS (S3 Table). For BMI-associated OE signals that could not be com-
pared directly in MCDS (i.e. unknowns or unshared knowns), we applied our matching
procedure, and found 322 out of 425 (89.2%) “reciprocal” or 543 out of 790 (68.7%) “multiple”
matched signal pairs to have directionally consistent and nominally significant association in
MCDS (S3 Table). Again, by checking if these signal pairs contained known metabolites or
had m/z matching adduct masses recorded in HMDB, we found 61 replicated "reciprocal"
matched signal pairs to be potentially redundant with the measured known metabolites, 119
pairs to be related to HMDB metabolites not identified in our data, and 142 pairs with unre-
corded m/z values. For replicated "multiple" matched signal pairs, 112 were related to mea-
sured knowns, 207 were related to other HMDB metabolites, and 224 were unrecorded in
HMDB. Thus, by matching signals across OE and MCDS, we replicated 3.5–5.8 times more
Fig 2. Genetic validation of OE-MCDS matched signals. GWAS were performed for “multiple” matched signal pairs (a subset of which were “reciprocal”),
shared known pairs (“Shared Known”, positive control), and randomly matched pairs (average statistics shown as “Random”, negative control) in OE and
MCDS, followed by meta-analysis that ignored direction of effect. For each pair, the SNP with the best meta-analyzed p-value was selected to assess directional
consistency of its association in the two cohorts. (a) “Total # of Pairs”: number of signal pairs with best SNPs below p-value threshold; (b) “# of Consistent
Pairs” and (c) “Fraction of Consistent Pairs”: number and fraction of pairs with directionally consistent best SNPs below p-value threshold; (d) “# of True
Positive Pairs” and (e) “Fraction of True Positive Pairs”: number and fraction of true positive pairs were estimated as described in Methods. X-axes start at
genome-wide significant p-value threshold (p< 5 × 10−8). Error bars for “Random” pairs were excluded due to low visibility (all close to average).
https://doi.org/10.1371/journal.pcbi.1006734.g002
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BMI-associated signals compared to only looking at known metabolites identified in our data-
sets. Even if the unknown signals are not completely independent (i.e. multiple signals might
correspond to one functional metabolite), the additional biological information extracted
from the unknowns can be useful in pathway-based analyses that account for redundancy
among signals, which we explored in the following section.
Generating pathway annotations for metabolite signals
Pathway method overview and calibration. Metabolic pathway annotations in public
databases contain rich information for characterizing metabolites. However, these annotations
are usually binary (i.e. a metabolite is either in or out of a pathway with no uncertainty) and
only involve metabolites with known identities. Thus, in order to predict functions of
unknown signals in our data and to perform well-powered pathway analysis, we developed an
approach to assign metabolite signals to previously curated pathways (Fig 1B). First, we used
profiling data from the BioAge cohort to construct “metabolic components” (MCs) that repre-
sent modules of covarying signals (S8 Fig). Next, we collected metabolic pathway annotations
from ConsensusPathDB (CPDB) [17] and consolidated them into metabolite sets with unique
metabolite combinations (i.e. one metabolite set may correspond to multiple pathways that
contain identical sets of metabolites). We used the MCs to extend (reconstitute) the metabolite
sets to include both known and unknown signals, resulting in a numeric signal-metabolite set
annotation matrix, in which each signal was assigned a membership score in each set based on
its similarity (across MCs) to metabolites originally curated to be in the set.
After reconstitution, we calculated a “label confidence score” to indicate how similar each
reconstituted metabolite set is to the original pathways labeling the set; we also tested how well
the reconstituted membership scores could be used to classify known metabolites into their
original metabolite sets (see Methods). Using these performance measures, we calibrated dif-
ferent parameters in the reconstitution procedure (i.e. which metabolite sets and MCs to
include) and picked the best-performing settings to construct the final BioAge annotation
matrix (S9 Fig and S4 Table). Furthermore, to assess how sample size and number of known
metabolites in the profiling dataset used for reconstitution would affect outcome, we carried
out additional reconstitution analyses using random subsets of BioAge samples or known
metabolites (S10 Fig). While we observed that larger sample size and known metabolite count
both led to better reconstitution performance, increase in known metabolite count had a more
dramatic influence compared to increase in sample size. When there was sufficient number of
known metabolites in the dataset, relatively few samples were required to achieve good perfor-
mance (S10A Fig).
Genetic validation of pathway annotations. We utilized OE genetic data to validate that
the BioAge annotation matrix captures biologically relevant relationships. Specifically, we tested
whether metabolite signals genetically associated with a gene would be enriched for reconsti-
tuted pathways related to that gene. First, we performed exome chip association analyses for all
OE metabolite signals, mapped the signals with suggestive associations (p< 1 × 10−5) to BioAge
using our matching procedure (in “multiple” setting), and derived a total of 6,465 associations
between OE exome SNPs and BioAge matched signals. Next, we filtered the association results
to select 36 loci that (1) contain coding SNPs associated with> = 5 signals and (2) contain
genes curated to be in pathways reconstituted in the BioAge annotation matrix.
For each locus, we first used the BioAge annotation matrix to prioritize reconstituted
metabolite sets enriched for the SNP-associated signals, and then checked whether the gene-
related pathways showed up as enriched in the analysis. As negative control, we also repeated
this procedure using 20 iterations of null association results. At an enrichment significance
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cutoff of p< 0.01, 5 out of 36 loci had gene-related enriched pathways (Table 2), compared to
a mean of only 0.85 loci in null results (empirical p< 0.05; S5 Table). Even at less stringent
enrichment significance thresholds, our approach performed better compared to null
prioritization.
Examples of successful validation. We highlight three loci in which the enriched path-
ways have clear relevance to the affected genes’ functions. First, SNP rs5030858 causes a mis-
sense mutation (R408W) in PAH, which encodes the phenylalanine hydroxylase responsible
for converting phenylalanine to tyrosine, and the mutation is known to cause phenylketonuria
[18]. In our analysis, the SNP was associated with phenylalanine, cholate, and 10 unknown sig-
nals. We performed m/z queries for the unknowns in HMDB and retrieved potential identities
for 7 of the signals (S6 Table). In particular, one signal may be an adduct of phenylalanine (or
a phenylalanine isomer); two others may be related to cinnamic acid and hypoxanthine, both
of which have been linked to phenylalanine metabolism [19, 20]. On the other hand, 3 signals
had no m/z record in HMDB and may be capturing metabolites that are underexplored in the
human body, or even novel molecules that have not been characterized at all. The SNP-associ-
ated signals were enriched in 83 metabolite sets (corresponding to 129 pathways) at p< 0.01,
with 8 of these sets containing pathways directly linked to PAH in CPDB (Table 2). Many
other enriched sets are also related to phenylalanine and tyrosine metabolism, such as those
involved in amine, neurotransmitter, and tryptophan metabolism (S7 Table).
Next, SNP rs36004833 is a missense variant (P451S) in SLC13A4 and was associated with
creatine, sarcosine, and 7 unknowns. HMDB m/z search showed that 3 of the unknowns may
be adducts of creatine, 3 other signals matched (and thus may represent) adducts of creatinine,
neohesperidin dihydrochalcone, and canavanine, and the last signal had no m/z record (S6
Table 2. Top loci identified during genetic validation of BioAge pathway annotations.
Locus
(SNP)
Chr Alleles Gene Mutation Associated signals� Enriched pathways (p< 0.01) linked to gene
rs1105879 2 A/C UGT1A6 R184S 1-methylnicotinamide, 54
unknowns
EHMN:Porphyrin metabolism; KEGG:Porphyrin and chlorophyll
metabolism—Homo sapiens (human); Reactome:Metabolism of porphyrins
rs36004833 7 A/G SLC13A4 P451S creatine, sarcosine, 7 unknowns Reactome:SLC-mediated transmembrane transport; Reactome:Transport
of glucose and other sugars, bile salts and organic acids, metal ions and
amine compounds
rs5030858 12 C/T PAH R408W phenylalanine, cholate, 10
unknowns
Reactome:Metabolism of amino acids and derivatives; Wikipathways:
Biogenic Amine Synthesis; Wikipathways:SIDS Susceptibility Pathways;
Reactome:Phenylalanine and tyrosine catabolism; SMPDB:Tyrosinemia
Type 2 (or Richner-Hanhart syndrome); SMPDB:Phenylalanine and
Tyrosine Metabolism; SMPDB:Phenylketonuria; SMPDB:Tyrosinemia
Type 3 (TYRO3); KEGG:Phenylalanine, tyrosine and tryptophan
biosynthesis—Homo sapiens (human); KEGG:Phenylalanine metabolism
—Homo sapiens (human); HumanCyc:phenylalanine degradation/
tyrosine biosynthesis
rs30842 16 T/G GOT2 V346G 5 TAGs (C46:2, C46:3, C48:3,
C48:4, C48:5), 6 unknowns
INOH:Glycine Serine metabolism; SMPDB:4-Hydroxybutyric Aciduria/
Succinic Semialdehyde Dehydrogenase Deficiency; SMPDB:Glutamate
Metabolism; SMPDB:2-Hydroxyglutric Aciduria (D And L Form); SMPDB:
Hyperinsulinism-Hyperammonemia Syndrome; SMPDB:Succinic
semialdehyde dehydrogenase deficiency; SMPDB:Homocarnosinosis; INOH:
Phenylalanine degradation; HumanCyc:4-hydroxyproline degradation;
KEGG:Phenylalanine metabolism—Homo sapiens (human)
rs11657051 17 C/T ARSG R398W 26 unknowns Reactome:Gamma carboxylation, hypusine formation and arylsulfatase
activation
Bolded loci are discussed in main text. Pathway names are separated by “;”.
� Unique BioAge signals matched to associated (p< 1 × 10−5) OE signals are shown.
https://doi.org/10.1371/journal.pcbi.1006734.t002
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Table). However, we noted that the retention times for all of these unknowns (8.38–8.39 min)
were close to that of creatine (8.38 min), thus they may have originated from creatine or other
structurally similar metabolites. SLC13A4 encodes a sodium/sulfate cotransporter that is
known to be expressed in the high endothelial venules [21], and two of the metabolite sets
enriched for the SNP-associated signals contain pathways linked to SLC13A4 (“Reactome:
SLC-mediated transmembrane transport” and “Reactome: Transport of glucose and other sug-
ars, bile salts and organic acids, metal ions and amine compounds”; Table 2 and S8 Table).
Importantly, the SNP-associated known metabolites, creatine and sarcosine, were not origi-
nally curated to be in these pathways in CPDB, thus the pathways could not have been detected
without using our method.
Finally, SNP rs11657051 causes a missense mutation (R398W) in ARSG (Arylsulfatase G)
[22] and was tentatively associated with 26 unknown signals (minimum p< 1.72 × 10−7).
Most of the unknowns had no m/z record in HMDB, with only 4 signals potentially linked to
chlorate, glutamine, and two metabolites found in cell membrane (a n-acyl pyrrolidine and a
sphinogomyelin; S6 Table). However, upon closer inspection, we noted that except for the
potential glutamine adduct (HILIC-pos_QI2842), the unknowns had similar retention times
(7.64–7.65 min) and recurring m/z differences from each other, indicating that they may be
potassium formate ion clusters formed as artifacts during the profiling procedure (S9 Table)
[23]. Intriguingly, despite their likely non-biological nature, we were able to prioritize path-
ways directly or indirectly linked to ARSG using these SNP-associated unknowns (e.g. “Reac-
tome: Gamma carboxylation, hypusine formation and arylsulfatase activation” and
“Reactome: Heparan sulfate/heparin (HS-GAG) metabolism”; Table 2 and S10 Table), due to
correlation between these unknowns and known metabolites. The tentative nature of the
genetic associations and the likely artefactual nature of the unknowns mean that future valida-
tion of the correlations with known metabolites and additional investigation would be needed
to understand whether and how this group of ARSG-associated unknowns was able to capture
biologically relevant information related to ARSG activity.
Together, the genetic validation examples discussed in this section showcase how our
approach can link both known and unknown metabolite signals to various biological pathways
and functions. In some cases, unknown signals may serve as “proxies” that tag true biology
even when they might not be biological and functional entities themselves.
Application to identify BMI-associated pathways. As a last demonstration of the utility
of PAIRUP-MS, we applied both the signal matching and pathway annotation methods to
identify metabolic pathways associated with BMI. First, we identified 1,474 and 1,289 signals
associated with BMI in OE and MCDS, respectively (after correction for multiple testing), and
matched the unshared signals from each cohort to a common reference cohort (BioAge) using
the “multiple” match type setting. Between shared knowns and matched signals, we could map
a total of 1,162 OE and 1,030 MCDS BMI-associated signals to BioAge. We performed separate
pathway enrichment analyses using these two sets of signals and the BioAge reconstituted
metabolite sets. In total, 218 (31.6%) and 179 (25.9%) out of 690 metabolite sets were enriched
(FDR< = 5%) for the OE- and MCDS-matched signals, respectively (S11 Table). A total of
107 (15.5%) metabolite sets, corresponding to 215 pathways, were enriched in both analyses
(overlap significance: Fisher’s p = 4.01 × 10−20; Fig 3). These pathways are involved in a wide
range of biological processes, including signal transduction, neurotransmission, synaptic func-
tion, macronutrient metabolism, immune system, and transport of various compounds.
To show that our methods increased power for detecting BMI-related pathways, we per-
formed traditional overrepresentation analyses using only the BMI-associated known metabo-
lites and the binary metabolite set annotations from CPDB, and found only 25
overrepresented sets for OE at 5% FDR, while MCDS had no significant sets at all (S12 Table).
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These results demonstrate that PAIRUP-MS can be used to incorporate unknown signals into
pathway-based analyses, thereby improving both power and interpretation in metabolomics
studies.
Discussion
While untargeted profiling generates data for thousands of metabolite signals, most signals
cannot be readily identified as known metabolites, are difficult to compare across studies, and
consequently are often excluded from downstream analyses. In order to facilitate better use of
untargeted data, we have developed PAIRUP-MS, an integrative tool for processing, matching,
and annotating the unknown signals, which allowed us to compare them across MS-based
datasets, extract useful information from their data, and improve power at detecting trait-asso-
ciated biology. To our knowledge, no existing tools provide a similar streamlined and flexible
framework for dealing with unknown signals across multiple datasets. Furthermore, unlike
Fig 3. Clustered correlation heat map of 107 metabolite sets enriched (5% FDR) for both OE and MCDS BMI-associated signals. Correlation between
metabolite sets were calculated using the BioAge annotation matrix. Color key indicates correlation values between each pair of metabolite sets. Distinct
clusters (blue boxes with labels A-J) are highlighted, with representative pathway names in the clustered metabolite sets shown to the right of the heat map.
https://doi.org/10.1371/journal.pcbi.1006734.g003
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previous methods designed to analyze unknown metabolites using specific biological variables
(e.g. disease phenotype), PAIRUP-MS depends only on the metabolite profiling data to match
and annotate the unknowns, before any additional data is required to perform downstream
analyses.
Within PAIRUP-MS, we implemented a m/z and imputation-based method for matching
unknown signals across datasets, demonstrated that it could be used to accurately pair up
shared known metabolites, and showed that it could outperform a m/z and RT-based match-
ing approach when RT information is unreliable. When we used genetic associations to vali-
date a subset of the matched signals, we observed that the most stringent matches performed
comparably in validation to the shared knowns. By including matched signals in combined
association analyses (with genetic variants or with phenotypes), we were able to identify ~6
times more signals with significant replicated associations compared to the common practice
of only studying known metabolites.
We also developed a pathway reconstitution procedure to annotate unknown signals using
curated metabolic pathways. Again, we used genetic data to validate the pathway annotations,
showing that signals associated with a gene were likely to be enriched for the gene-related
pathways. Finally, we applied both the matching and pathway methods to identify BMI-associ-
ated pathways using a crossover approach (i.e. identifying trait-associated signals in one data-
set but testing for enrichment using pathways built from another dataset), and demonstrated
that it was more powerful than performing pathway overrepresentation analysis using only
known metabolites.
Several study limitations and future directions should be considered. First, although the
samples encompassed a range of ascertainments and were collected in different continents, all
three datasets were generated by the same LC-MS profiling platform (albeit over different iter-
ations of that platform). It will be valuable to test PAIRUP-MS using data from other plat-
forms, as performance may be influenced by various technical differences between platforms
(e.g. experimental setups of profiling assays, computational software used to detect signal
peaks, types of metabolites measured and identified, etc.). The pathway method should be
applicable to any profiling dataset that has sufficient number of samples and identified known
metabolites, whereas the matching method is restricted to MS-based datasets with comparable
metabolite correlation structures. We provide some guidelines for minimum requirements for
using PAIRUP-MS, but calibrating parameters and assessing performance using known
metabolites, as we have described in this study, will still be crucial to achieving good results
when analyzing data from diverse studies and platforms.
Another study limitation concerns the fact that we only performed computational valida-
tion of PAIRUP-MS results in this paper. While our validation approaches enable systematic,
unbiased assessment of results, they require genetic data to be available for the profiled sam-
ples. In particular, we could only validate OE-MCDS matched signals because BioAge geno-
types were unavailable, and even the OE and MCDS cohorts had ancestry differences that
complicated the interpretation of results (i.e. hard to determine if failed validation was due to
false match or genetic difference). Larger numbers of untargeted profiling datasets with
accompanying genetic data will allow the ongoing use of genetic data to assess the performance
of PAIRUP-MS across a wider range of samples.
Experimental validation of the unknown signals is also an important future direction.
Although PAIRUP-MS allows us to analyze unknown signals without knowing their chemical
identities, individual signals of interest would ultimately have to be chemically characterized if
we are to fully understand their biological functions. We performed m/z queries in HMDB to
determine the potential identities of some unknown signals highlighted in this paper, but it is
not possible to confirm these identities and distinguish between various adducts and isomers
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without additional targeted profiling experiments. Moreover, as illustrated by the ARSG
genetic validation example, even when unknown signals appear to be informative for biologi-
cal inference, they may be non-biological entities that are correlated with functional metabo-
lites. In this particular example, the likely artefactual nature of the unknowns means that
independent confirmation of their correlations with known metabolites and with genetic vari-
ation in ARSG would be needed. If these correlations, especially with genetic variation at
ARSG, were validated, it would raise the intriguing hypothesis that these non-biological enti-
ties may be an indirect readout of true biological variation across samples; in this case, further
work would be required to identify the true biological connections.
Despite these caveats, by initially skipping over the bottleneck of metabolite identification,
PAIRUP-MS offers a powerful way to prioritize unknown signals, so identification efforts can
be focused on the unknowns that show the most robust biological or clinical significance
across multiple cohorts. Furthermore, since the pathway annotation method in PAIRUP-MS
can be used to classify unknown signals into previously defined metabolic pathways, it can
provide an additional piece of information for deriving the identities of the unknowns. Once
the identity of an unknown signal has been successfully validated, it can in turn be used as a
known metabolite in new PAIRUP-MS analyses to improve functional prediction for the rest
of the unknowns. In the future, experimental validation of unknown signals prioritized by
PAIRUP-MS should be performed to assess how successfully PAIRUP-MS and metabolite
identification can be used to complement each other in a synergistic manner.
The matching approach in PAIRUP-MS can also be combined with previous methods that
have been developed around the concept of using biologically meaningful associations (e.g.
with genetic variation or with disease phenotype) to prioritize unknown signals for follow-up
investigation [10, 14, 15]. These methods were designed to be applied to one untargeted dataset
at a time and thus may have power to detect only the very strongest associations. By harmoniz-
ing unknown signals across datasets using only the metabolite data itself (i.e. without using
genetic or other phenotypic information), PAIRUP-MS can enhance the applications of these
methods, allowing them to be used to analyze joint datasets of larger sample sizes, thus increas-
ing the number of robust associations that can be detected between the unknowns and other
genetic or phenotypic variables.
Finally, while we focused on analyzing pairs of datasets in this paper, large-scale meta-anal-
ysis requires a framework to match and compare many datasets simultaneously. Our current
recommendation would be to define a “reference panel” dataset and match metabolite signals
in all other datasets to this common reference (analogous to reference panels for genotype
imputation). The choice of the reference panel could be made after assessing the performance
of matching shared known metabolites across pairs of datasets. A reference dataset that incor-
porates diverse samples and captures a wide range of metabolite abundance variation would
also be ideal for building reference pathway annotations that can be used to annotate all signals
that are matched to the reference.
In conclusion, we have developed a suite of methods, PAIRUP-MS, for analyzing unknown
signals in untargeted profiling data and showed that it can be applied to improve power and
make biological inferences in metabolomics analyses. Matching across datasets is vital for
increasing power through meta-analysis (e.g. imputation enabled meta-analysis of GWAS data
across different genotyping platforms). Similarly, PAIRUP-MS can enable much more power-
ful analyses and meta-analyses of the great majority of untargeted metabolomics data that has
not yet been systematically examined. The availability of many more untargeted datasets (espe-
cially with accompanying genetic data) will allow these analyses to be performed in much
larger sample sizes and should also allow further refinement and evaluation of our methods
across a wider range of datasets, samples, and platforms.
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Methods
Metabolomics datasets and data processing
Obesity Extremes cohort (OE). Metabolite profiling was performed on plasma samples
of 300 individuals from the Estonian Biobank of the Estonian Genome Center at the Univer-
sity of Tartu (EGCUT) [24]. The individuals were selected from the extremes of the BMI distri-
bution to include 100 lean (BMI < 20), 100 obese (BMI > 34), and 100 random individuals
matched for age, sex, and fasting time (> = 4 hr). Clinical data were examined to exclude any
individuals with pregnancy, anorexia, or known wasting illnesses. Profiling was done using 4
LC-MS methods to measure 393 known metabolites and 18,667 unknown signals.
Mexico City Diabetes Study cohort (MCDS). Metabolite profiling was performed on
fasting plasma samples collected from 865 individuals in the Mexico City Diabetes Study at the
1998 exam cycle. Details of this prospective cohort have been described previously [25]. 3
LC-MS methods were used to measure 306 known and 11,888 unknown signals.
BioAge Labs Mortality cohort (BioAge). Metabolite profiling was performed on plasma
samples of 583 individuals 70–80 years old and free of major morbidity at enrollment, selected
from the Estonian Biobank as a mortality cohort. None of the BioAge samples overlap with
OE. 4 LC-MS methods were used to measure 629 known and 19,087 unknown signals.
Metabolite data processing. An overview of the data processing scheme is shown in S1
Fig. Starting with datasets in which signal peaks have been detected, aligned and quantified
and where several hundred known metabolites have been identified, we performed the follow-
ing steps on each dataset before using it in downstream analyses: (1) log-transformed and nor-
malized the data using internal standards and interspersed pooled plasma samples, (2)
removed outlier data points and signals with noisy variation trends, (3) removed samples and
signals with> 25% (OE) or 50% (MCDS and BioAge) missing data, (4) imputed missing val-
ues using the MICE R package (v2.25) [26], (5) adjusted each signal for covariates if appropri-
ate (only done for data used in genetic and BMI association analyses: age, sex, and fasting time
for OE; age and sex for MCDS), and (6) performed rank-based inverse normal transformation
to calculate abundance z-scores for each signal.
All participants in OE, MCDS, and BioAge provided informed consent. This study was
approved by their respective local ethics committees and the Boston Children’s Hospital Insti-
tutional Review Board. More details of the metabolite profiling, quality control, and missing
value imputation procedures are described in S1–S3 Text.
Matching metabolite signals across datasets
Checking for m/z agreement. We implemented an algorithm to check whether the differ-
ence between 2 m/z values are within d ± 0.005 of each other. While d = 0 in the most basic set-
ting, it can be set to multiple values when taking ionization modes and adduct ions into
account as shown in S13 Table. In particular, we implemented 2 settings: (1) “No adduct”:
only the most common positive or negative adduct ion (i.e. [M+H]+ and [M+H]-) is consid-
ered, or (2) “Adduct”: multiple adduct ions are considered. (In this paper, we selected the ions
used in “adduct” setting by observing m/z differences between shared known metabolites in
our datasets: we included M+, [M+H]+, [M+NH4]
+, and [M+Na]+ for positive ionization
mode and [M-H]- for negative ionization mode. However, additional or alternative adduct
ions may be specified when running the algorithm to accommodate different types of datasets
to test whether different sets of adducts improve matching performance.) When identifying all
signal pairs with agreeing m/z values across two datasets, we also implemented a third “com-
bined” setting, where the “adduct” setting was used only when the “no adduct” setting failed to
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identify any pairs with matching m/z values. We tested all 3 settings in Parameter calibration
to identify the optimal setting to use for matching signals across each pair of datasets.
Calculating imputation-based correlation. To impute a signal from Dataset 1 to Dataset
2, we fit a linear regression model for the signal using Dataset 1 data, which included all
known metabolites shared by the two datasets as predictors, and then applied the resulting
model to Dataset 2 data to predict the signal’s abundance in Dataset 2 samples. The reversed
process was done to impute signals from Dataset 2 to Dataset 1. When performing imputation
for the shared knowns (used as positive controls in Parameter calibration), we built a leave-
one-out model for each known metabolite m, where all shared knowns except for m were used
as predictors. After imputation, we calculated pairwise correlation between Dataset 1 and
Dataset 2 signals using 3 different settings: (1) “Dataset 1 correlation”: correlate Dataset 1
(observed) and Dataset 2 (imputed) signals across Dataset 1 samples, (2) “Dataset 2 correla-
tion”: correlate Dataset 1 (imputed) and Dataset 2 (observed) signals across Dataset 2 samples,
or (3) “All correlation”: merge observed and imputed data and correlate signals across all sam-
ples. We evaluated these settings in Parameter calibration to identify the optimal approach to
use for Matching based on m/z and correlation.
Matching based on m/z and correlation. In general, to match a Dataset 1 signal, s, to a
Dataset 2 signal, we would first identify all Dataset 2 signals whose m/z agree with s, and then
select the one that is best correlated with s to be the final match. If no Dataset 2 signals share
matching m/z with s, then s is not matched at all. We implemented variations of this procedure
and compared their performance in Parameter calibration. First, since the matching procedure
is directional (i.e. matching from Dataset 1 to 2 vs. 2 to 1 could be different), we distinguished
between 3 types of matches, each type being a subset of the previous type: (1) “Multiple”: all
matches that can be made as described by the general guideline above, which allows multiple-
to-1 matching (i.e. multiple Dataset 1 signals can be mapped to the same Dataset 2 signal), (2)
“Unique”: unique 1-to-1 matches that only keep the best (in terms of correlation) Dataset 1 sig-
nal mapped to each Dataset 2 signal, or (3) “Reciprocal”: unique, bidirectional 1-to-1 matches
that appear both when matching from Dataset 1 to 2 and from 2 to 1. We also allowed 2 parti-
tion settings: (1) “Within method”: only look for matches among signals measured using the
same profiling method, or (2) “Across method”: look for matches across datasets regardless of
differences in profiling methods. Lastly, we implemented an optional correlation cutoff for call-
ing matches (i.e. only keep matched pairs whose correlation is greater than the cutoff).
Matching based on m/z and RT. We implemented a crude RT-based matching procedure
to serve as a comparison to our imputation-based method. Here, to match signals from Dataset
1 to Dataset 2, we would first use RTs of shared knowns to fit a linear model for predicting the
RT shift between the two datasets. Then, to match a Dataset 1 signal, s, to a Dataset 2 signal, we
would predict the RT of s in Dataset 2 using the fitted model, find all Dataset 2 signals whose
m/z agree with s, and then select the one whose RT is closest to the predicted RT to be the final
match. Just as we did for Matching based on m/z and correlation, we tested different match
types (“multiple”, “unique”, or “reciprocal”) and partition settings (“within method” or “across
method”) in Parameter calibration.
Parameter calibration. To calibrate all of the parameters described above (i.e. adduct ion
setting, correlation setting, match type, partition setting, and correlation cutoff), we treated
known metabolites shared across two datasets as unmatched signals and applied our proce-
dures to match them up. For each pair of datasets (i.e. OE-MCDS, OE-BioAge, or MCDS-Bio-
Age), we calculated the number and percentage of (1) correct matches: Dataset 1 metabolite is
matched to itself in Dataset 2, (2) highly correlated matches: Dataset 1 metabolite is matched
to a signal that is highly correlated (r2 > 0.8) with itself in Dataset 2, and (3) incorrect but
highly correlated matches: matches in (2) but not in (1).
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GWAS and genetic validation of matched signals
GWAS and meta-analysis. 294 OE samples with Estonian reference imputed genotypes
and 637 MCDS samples with 1000 Genomes phase 3 imputed genotypes were used to perform
GWAS for the OE-MCDS shared known and matched signal pairs (see S4 Text for genotyping
and imputation details). We used the linear mixed model and kinship matrix calculation meth-
ods in EPACTS (v3.2.6) [27] to analyze each cohort, restricting analyses to biallelic SNPs with
minor allele count> = 3 in the cohort and including genotyping platform/backbone as a
covariate. SNPs that overlap between the 2 cohorts were meta-analyzed using the inverse vari-
ance weighted method in METAL (2011-03-25 version) [28].
Validation analysis. For each pair of shared knowns or matched signals, we performed an
alternative meta-analysis that ignored direction of effect (i.e. forcing all effect size estimates to
be positive), identified the SNP with the best meta-analyzed p-value, and determined if its origi-
nal effect size estimates in OE and MCDS were directionally consistent. We combined results
for individual signal pairs to calculate the number and fraction of consistent pairs among shared
knowns or matched signals at different p-value thresholds (i.e. only considering pairs whose
best SNPs pass the threshold). We used Fisher’s exact test to evaluate statistical significance of
the observed degree of consistency. Additionally, for the matched signals, we performed 20 null
permutations by shuffling the mapping between matches (i.e. generating randomly matched
pairs), and then calculated an empirical p-value for the observed consistency fraction (i.e. p =
proportion of null fractions greater than or equal to the observed fraction). Finally, we estimated
the fraction of true positive pairs (i.e. true positive rate) at each p-value threshold to be: max[(c–
0.5)/(s– 0.5), 1] where c = fraction of consistent pairs and s = fraction of consistent shared
knowns, and then derived the number of true positive pairs using this fraction.
Generating pathway annotations for metabolite signals
Metabolic pathway and metabolite set annotations. We collected metabolic pathway
annotations from CPDB (release 31) [17], which aggregated data from 11 source databases.
We filtered the annotations to obtain pathways containing > = 2, 5, or 10 known metabolites
profiled in BioAge and assigned a “database:name” label to each pathway, where database
refers to the source database and name is the pathway name as shown in that database. We fur-
ther consolidated the pathways into metabolite sets, with each set representing all pathways
sharing the same metabolite combination, excluding metabolites not profiled in BioAge. The
resulting metabolite set annotations were used as input data in Signal-metabolite set annota-
tion matrix. CPDB also contains annotations that link genes to pathways based on previous
literature evidence, which we utilized in Genetic validation of pathway annotations.
Metabolic components. We calculated pairwise Spearman correlation for all metabolite sig-
nals (known and unknown) across BioAge samples, and then performed principal component
analysis on the correlation matrix to derive “metabolic components” (MCs; eigenvectors that rep-
resent modules of correlated signals) and a corresponding signal-MC score matrix. In order to
assess if the MCs captured biological patterns contained within metabolite sets derived from
CPDB, we performed enrichment analysis using the MC scores of known metabolites included in
the metabolite sets. For each MC and each set, we performed a two-tailed Wilcoxon rank-sum test
to compare the MC scores of metabolites in the set vs. other metabolites. We repeated the tests
using 20 iterations of null, permuted MC scores and estimated the FDR for each observed rank-
sum p-value threshold, P, to be: (average number of null p-values< = P per iteration) / (number of
observed p-values< = P). This FDR was used to filter MCs as described in Parameter calibration.
Signal-metabolite set annotation matrix. We used the MC scores of metabolite signals
to reconstitute the CPDB metabolite sets, adopting a previously described framework for gene
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set reconstitution [29]. Again, we performed a two-tailed Wilcoxon rank-sum test to compare
the MC scores of known metabolites in the set vs. not in the set for each metabolite set-MC
pair, but this time storing the results as a metabolite set-MC matrix of rank-sum z-scores. Next,
we used the signal-MC matrix (from Metabolic components) and the metabolite set-MC
matrix to calculate the Spearman correlation between each signal-metabolite set pair across the
MCs, resulting in a signal-metabolite set annotation matrix of correlation scores. To avoid over-
fitting, when calculating the matrix scores of a known metabolite originally annotated in a set,
we repeated the reconstitution procedure by leaving out the data for this metabolite.
Parameter calibration. A calibration procedure was carried out to determine which metab-
olite sets and MCs to use for constructing the optimal signal annotation matrix. We tested
metabolite sets containing> = 2, 5, or 10 known metabolites profiled in BioAge. For MCs, we
tested the top 50, 100, or 583 MCs (in terms of variance explained), or filtered for any MCs that
were enriched for> = 1 metabolite set at 1% or 5% FDR (see Metabolic components). After
generating annotation matrices using different parameters, for each matrix, we converted corre-
lation scores of known metabolites into p-values, and then evaluated how well these p-values
could be used to classify metabolites into their original metabolite sets using a receiver operating
characteristic (ROC) curve and area under the curve (AUC) approach. We also performed post-
reconstitution enrichment analysis to identify reconstituted metabolite sets enriched for metab-
olites originally curated to be in the set (see Metabolite set enrichment analysis). The enrich-
ment p-values from this analysis were used as “label confidence scores” for the metabolite sets.
Genetic validation of pathway annotations
Exome chip association analysis. A subset of 281 OE samples were genotyped using the
Illumina HumanOmniExpressExome BeadChip (v1.2). We performed association analysis for
each OE metabolite signal using this genetic dataset to identify exome SNPs associated with sig-
nal abundance. We restricted our analyses to 57,220 exome SNPs with minor allele count> = 3
and call rate> = 0.5 in OE, using the linear mixed model and kinship matrix calculation meth-
ods in EPACTS (v3.2.6) [27].
Validation analysis. We filtered the OE exome chip association results using OE-BioAge
“multiple” matched signals to identify associations between OE SNPs and BioAge signals. We
grouped the associations by SNPs and identified SNPs that (1) were associated with> = 5 sig-
nals at p< 1 × 10−5, (2) cause missense or nonsense mutations in genes, and (3) affect genes
linked to> = 1 CPDB pathways used for reconstitution. If multiple SNPs were found for the
same gene, we only kept the SNP with the best p-value. To perform validation analysis for each
locus, we first used the BioAge signal annotation matrix to prioritize metabolite sets enriched
for the SNP-associated signals (see Metabolite set enrichment analysis). Next, we determined
if any pathways linked to the affected gene showed up as enriched across a range of enrichment
p-value thresholds. For each threshold, we counted the number of loci for which> = 1 gene-
associated pathway was enriched, and then repeated the procedure using 20 iterations of null
exome chip association results (i.e. identifying top signals associated with random genotypes)
to generate null counts for comparison. We calculated the empirical p-value for the observed
count to be the proportion of null counts > = the observed count.
BMI-associated metabolite signals and metabolite sets
Metabolite signals. We calculated BMI z-scores for both OE and MCDS samples by
adjusting raw BMI for age and sex and performing rank-based inverse normal transformation
on the residuals. For OE, all samples in the Estonian Biobank were included during z-score
calculation; for MCDS, only samples in the cohort were included. We performed linear
Analyzing unknown signals in mass spectrometry-based metabolite data
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1006734 January 14, 2019 18 / 26
regression to test for association between BMI z-scores and signal abundance z-scores in both
cohorts and identified BMI-associated signals at Bonferroni-corrected significance thresholds
(p< 0.05/13,613 for OE; p< 0.05/7,136 for MCDS).
Metabolite sets. We identified BioAge shared knowns or “multiple” matched signals cor-
responding to the BMI-associated OE and MCDS signals from the previous section, and then
used these signals and the BioAge signal annotation matrix to perform two separate enrich-
ment analyses as described in Metabolite set enrichment analysis. After identifying enriched
metabolite sets at 5% FDR in both analyses, we performed a Fisher’s exact test to evaluate the
statistical significance of the overlap.
Metabolite set enrichment analysis
A schematic overview of how we calculated statistical significance in metabolite set enrichment
analysis is shown in S11 Fig.
Rank-sum p-value. To calculate the enrichment of each metabolite set in the signal anno-
tation matrix given a “positive” and a “negative” list of signals, we used a two-tailed Wilcoxon
rank-sum test to compare the metabolite set scores (absolute correlation) of the positive vs.
negative signals to get a nominal p-value. For post-reconstitution enrichment analysis (in Gen-
erating pathway annotations for metabolite signals), the positive and negative lists consisted
of known metabolites in an original CPDB metabolite set vs. not in the set, respectively. For
identifying trait-associated metabolite sets, the lists consisted of signals significantly associated
with the trait (SNP genotype in Genetic validation of pathway annotations; BMI in BMI-
associated metabolite signals and metabolite sets) vs. all other signals (restricting to signals
that could be matched across datasets).
Permutation p-value. For Genetic validation of pathway annotations and BMI-associated
metabolite signals and metabolite sets, we generated null lists of signals ranked by their associa-
tion with 1000 sets of permuted trait scores and repeated the rank-sum tests using the null lists
(i.e. taking the top N signals in each null list to be the “positive” list, where N = the number of sig-
nals in the observed positive list). We used the null enrichment results to adjust the observed
rank-sum p-values for metabolite set-specific biases, calculating a permutation p-value for each
metabolite set to be the proportion of null rank-sum p-values< = the observed rank-sum p-value.
FDR. For BMI-associated metabolite signals and metabolite sets, we implemented
another level of permutations to estimate analysis-wide FDR that accounts for multiple
hypothesis testing across metabolite sets. We generated 20 additional null signal lists and cal-
culated their corresponding rank-sum p-values. By comparing these new null rank-sum p-val-
ues against the 1000 sets of null rank-sum p-values computed previously, we calculated 20 sets
of null permutation p-values. The FDR for an observed permutation p-value threshold, P, was
then estimated as: (average number of null permutation p-values < = P per null set) / (number
of observed permutation p-values < = P). Finally, we forced the final FDR estimates to be
monotonic (i.e. FDR for smaller p-values had to be< = FDR for larger p-values) to smooth
out random fluctuations in null iterations.
Metabolite set overrepresentation analysis
Binary metabolite set annotations from CPDB were used to perform overrepresentation analy-
sis given a list of trait-associated known metabolites. For each metabolite set, we created a
2 × 2 contingency table that categorized known metabolites based on trait association and
metabolite set membership and used it to calculate a one-sided Fisher’s exact p-value. Null per-
mutations were performed as described in Metabolite set enrichment analysis (except using
Fisher’s exact test instead of rank-sum test) to calculate permutation p-value and FDR.
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LC-MS m/z queries in HMDB
In order to determine potential identities of unknown signals prioritized in either the match-
ing or pathway results sections, we performed m/z queries using the “LC-MS Search” tool in
HMDB [16]. All adduct types (under the appropriate positive or negative ionization mode)
were considered. Molecular weight tolerance window was set to ± 1 ppm.
Supporting information
S1 Fig. Overview of PAIRUP-MS data processing scheme. Data processing steps performed
externally by Broad Metabolomics Platform or using existing software package (i.e. MICE) are
highlighted in blue. Steps performed separately on data generated from each profiling method
vs. on merged dataset containing data from all profiling methods are indicated by red text. All
components of PAIRUP-MS were designed to be run in a streamlined manner, but each com-
ponent can also be used independently depending on the characteristics of different datasets
and analysis needs (see source code and documentation on https://github.com/yuhanhsu/
PAIRUP-MS for details on input and output data format at each step).
(PDF)
S2 Fig. Comparison of known metabolite correlation structure between datasets. Pairwise
correlation between shared known metabolites were calculated within each dataset then com-
pared across (a) OE vs. MCDS, (b) OE vs. BioAge, and (c) MCDS vs. BioAge. R-squared (Rsq)
of the pairwise correlation values were calculated to assess overall similarity.
(PDF)
S3 Fig. OE-MCDS shared known matching calibration results. Matching was performed
using different adduct ion (a), correlation (b), match type (c), partition (d), and correlation
cutoff (x-axis) settings (see Methods for parameter explanations). In each panel, the parame-
ters not being compared were set to the following default values: “Adduct”, “All Correlation”,
“Reciprocal”, and “Within Method”. Dashed line in (b) shows optimal RT-based matching
results for comparison. “Match Count”: number of shared knowns matched; “Correct Frac-
tion”: fraction of correct matches; “Rsq0.8 Fraction”: fraction of matches strongly correlated
(r2 > 0.8) with the correct known in observed data; “Incorrect Rsq0.8 Fraction”: fraction of
incorrect matches strongly correlated with the correct known.
(PDF)
S4 Fig. OE-BioAge shared known matching calibration results. Matching was performed
using different adduct ion (a), correlation (b), match type (c), partition (d), and correlation
cutoff (x-axis) settings (see Methods for parameter explanations). In each panel, the parame-
ters not being compared were set to the following default values: “Combined”, “Dataset1 Cor-
relation”, “Reciprocal”, and “Within Method”. Dashed line in (b) shows optimal RT-based
matching results for comparison. “Match Count”: number of shared knowns matched; “Cor-
rect Fraction”: fraction of correct matches; “Rsq0.8 Fraction”: fraction of matches strongly cor-
related (r2 > 0.8) with the correct known in observed data; “Incorrect Rsq0.8 Fraction”:
fraction of incorrect matches strongly correlated with the correct known.
(PDF)
S5 Fig. MCDS-BioAge shared known matching calibration results. Matching was performed
using different adduct ion (a), correlation (b), match type (c), partition (d), and correlation
cutoff (x-axis) settings (see Methods for parameter explanations). In each panel, the parame-
ters not being compared were set to the following default values: “Combined”, “All Correla-
tion”, “Reciprocal”, and “Within Method”. Dashed line in (b) shows optimal RT-based
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matching results for comparison. “Match Count”: number of shared knowns matched; “Cor-
rect Fraction”: fraction of correct matches; “Rsq0.8 Fraction”: fraction of matches strongly cor-
related (r2 > 0.8) with the correct known in observed data; “Incorrect Rsq0.8 Fraction”:
fraction of incorrect matches strongly correlated with the correct known.
(PDF)
S6 Fig. Shared known matching performance using data containing different number of
samples and shared known metabolites. MCDS-BioAge matching was performed using (a)
random subsets of MCDS and BioAge samples (and 217 shared known metabolites) or (b) ran-
dom subsets of shared known metabolites (and 821 MCDS and 583 BioAge samples). For each
matching analysis, the fraction of matched knowns that was correct (“Correct”) or highly corre-
lated (“Rsq> 0.8”) with the correct match is plotted. In (a), “Number of Samples” indicates
sample size per dataset; red and blue dashed lines indicate the correct and highly correlated frac-
tions, respectively, when using all 821 MCDS and 583 BioAge samples to perform matching.
Optimal MCDS-BioAge matching parameters shown in S2A Table were used for all analyses.
(PDF)
S7 Fig. Genetic validation of OE-MCDS cross-method matched signals. GWAS were per-
formed for “multiple” matched signal pairs (a subset of which were “reciprocal”), shared
known pairs (“Shared Known”, positive control), and randomly matched pairs (average statis-
tics shown as “Random”, negative control) in OE and MCDS, followed by meta-analysis that
ignored direction of effect. For each pair, the SNP with the best meta-analyzed p-value was
selected to assess directional consistency of its association in the two cohorts. (a) “Total # of
Pairs”: number of signal pairs with best SNPs below p-value threshold; (b) “# of Consistent
Pairs” and (c) “Fraction of Consistent Pairs”: number and fraction of pairs with directionally
consistent best SNPs below p-value threshold; (d) “# of True Positive Pairs” and (e) “Fraction
of True Positive Pairs”: number and fraction of true positive pairs were estimated as described
in Methods. X-axes start at genome-wide significant p-value threshold (p< 5 × 10−8). Error
bars for “Random” pairs were excluded due to low visibility (all close to average).
(PDF)
S8 Fig. Characteristics of the BioAge metabolic components (MCs). Principal component
analysis was performed on the BioAge metabolite signal correlation matrix to derive the MCs.
(a) Cumulative variance explained (left y-axis) or Cronbach’s alpha (right y-axis) of the MCs.
(b) Number of CPDB metabolite sets that were enriched for each MC at 5% FDR.
(PDF)
S9 Fig. Calibration statistics for BioAge signal-metabolite set annotation matrix. Annota-
tion matrices generated using different combinations of (a) metabolite sets and (b) MCs were
used to classify known metabolites into their original metabolite sets, generating a ROC curve
(with corresponding area under the curve, AUC) for each matrix (see Methods for details). (c)
We also compared an annotation matrix containing only the confidently reconstituted metab-
olite sets (i.e. label confidence score < 0.05; “Filtered”) against the full matrix (“Unfiltered”).
In each panel, the parameters not being compared were set to the following default values:
“Metabolites = 2” (i.e. metabolite sets containing > = 2 metabolites), “MCs = fdr0.05” (i.e.
MCs enriched for > = 1 metabolite set at 5% FDR), and “Filtered”. “Null” statistics were calcu-
lated using permuted annotation matrix.
(PDF)
S10 Fig. Metabolite set reconstitution performance using data containing different num-
ber of samples and known metabolites. BioAge signal-metabolite set annotation matrices
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were generated using (a) random subsets of BioAge samples (and 603 known metabolites) or
(b) random subsets of known metabolites (and 583 samples). For each resulting annotation
matrix, the area under the curve (AUC) and the number or fraction of confidently reconsti-
tuted metabolite sets (i.e. label confidence score < 0.05) are plotted (see Methods for descrip-
tion of statistics). Metabolites sets containing > = 2 known metabolites and the top N MCs
(N = sample size) were included for reconstitution in each analysis.
(PDF)
S11 Fig. Calculating statistical significance in metabolite set enrichment analysis. (a) Rank-
sum p-value: Metabolite signals were split into positive (hatched pattern) and negative lists
based on association with a variable of interest (e.g. BMI). The lists were used to perform two-
tailed Wilcoxon rank-sum test to calculate observed (obs.) rank-sum p-value for each metabo-
lite set. 2 rounds of null permutations (i.e. associating signals with randomly permuted vari-
able) were used to calculate null rank-sum p-values. (b) Permutation p-value: Observed
permutation (perm.) p-value for each metabolite set was calculated by comparing the observed
rank-sum p-value against 1000 sets of null rank-sum p-values (from permutation round 1); 20
sets of null permutation p-values were calculated by comparing 20 sets of null rank-sum p-val-
ues (from permutation round 2) against another 1000 sets of rank-sum p-values (from permu-
tation round 1). (c) FDR: The analysis-wide FDR for an observed permutation p-value
threshold, P, was estimated by comparing the observed permutation p-values against the 20
sets of null permutation p-values.
(PDF)
S1 Table. Known metabolites included in QC’ed OE, MCDS, and BioAge metabolite data.
“NA”: m/z and RT information not available.
(XLSX)
S2 Table. (a) Optimal parameter settings and corresponding calibration statistics for match-
ing each pair of datasets. (b) Optimal parameter settings and corresponding calibration statis-
tics for cross-method matching.
(PDF)
S3 Table. BMI association results for OE-MCDS metabolite signal pairs. Metabolite signals
with profiling methods (HILIC-pos, C8-pos, or LIPID) as prefix in their names are unknowns.
Lipid name abbreviations: CE (Cholesteryl ester), DAG (Diacylglycerol), TAG (Triacylglycerol),
LPC (Lysophosphatidylcholine), LPE (Lysophosphatidylethanolamine), PC (Phosphtatidylcho-
line), PE (Phosphtatidylethanolamine), PI (Phosphtatidylinositol), PS (Phosphtatidylserine),
SM (Sphingomyelin). Other metabolite name abbreviations: ADMA (Asymmetric dimethylar-
ginine), NMMA (N-Monomethyl-L-arginine), SDMA (Symmetric dimethylarginine).
(XLSX)
S4 Table. Calibration statistics for BioAge signal-metabolite set annotation matrix.
(PDF)
S5 Table. Summary of genetic validation of BioAge pathway annotations.
(PDF)
S6 Table. Potential identities of unknown signals associated with rs5030858 (PAH),
rs36004833 (SLC13A4), or rs11657051 (ARSG) loci. “Potential identity”, “Chemical for-
mula”, “Adduct”, and “HMDB ID” information was retrieved by performing m/z query in
HMDB (see Methods).
(XLSX)
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S7 Table. Metabolite set enrichment results for signals associated with rs5030858 (PAH)
locus. “SET_ID”: unique identifier assigned to each metabolite set; “Nominal_P”: rank-sum p-
value; “Perm_P”: permutation p-value; “FDR”: false discovery rate of the permutation p-value;
“Label_P”: label confidence score for the reconstituted metabolite set; “CPDB_Pathways”:
labels for the original pathways from CPDB, individual pathways are separated by ‘|’.
(XLSX)
S8 Table. Metabolite set enrichment results for signals associated with rs36004833
(SLC13A4) locus. “SET_ID”: unique identifier assigned to each metabolite set; “Nominal_P”:
rank-sum p-value; “Perm_P”: permutation p-value; “FDR”: false discovery rate of the permuta-
tion p-value; “Label_P”: label confidence score for the reconstituted metabolite set;
“CPDB_Pathways”: labels for the original pathways from CPDB, individual pathways are sepa-
rated by ‘|’.
(XLSX)
S9 Table. Pairwise difference between m/z of signals associated with rs11657051 (ARSG)
locus (except HILIC-pos_QI2842).
(XLSX)
S10 Table. Metabolite set enrichment results for signals associated with rs11657051
(ARSG) locus. “SET_ID”: unique identifier assigned to each metabolite set; “Nominal_P”: rank-
sum p-value; “Perm_P”: permutation p-value; “FDR”: false discovery rate of the permutation p-
value; “Label_P”: label confidence score for the reconstituted metabolite set; “CPDB_Pathways”:
labels for the original pathways from CPDB, individual pathways are separated by ‘|’.
(XLSX)
S11 Table. Metabolite set enrichment results for BMI-associated signals in OE or MCDS.
“SET_ID”: unique identifier assigned to each metabolite set; “OE_Perm_P” or
“MCDS_Perm_P”: permutation p-value; “OE_FDR” or “MCDS_FDR”: false discovery rate of
the permutation p-value; “Label_P”: label confidence score for the reconstituted metabolite set;
“CPDB_Pathways”: labels for the original pathways from CPDB, individual pathways are sepa-
rated by ‘|’.
(XLSX)
S12 Table. Metabolite set overrepresentation results for BMI-associated known metabo-
lites in OE or MCDS. “SET_ID”: unique identifier assigned to each metabolite set;
“OE_Perm_P” or “MCDS_Perm_P”: permutation p-value; “OE_FDR” or “MCDS_FDR”: false
discovery rate of the permutation p-value; “CPDB_Pathways”: labels for the original pathways
from CPDB, individual pathways are separated by ‘|’.
(XLSX)
S13 Table. (a) Rules for checking for m/z agreement between 2 ions. (b) m/z values of differ-
ent adduct ions included in “adduct” settings.
(PDF)
S1 Text. Details of metabolite profiling.
(PDF)
S2 Text. Details of quality control (QC) of metabolite data.
(PDF)
S3 Text. Details of missing value imputation for metabolite data.
(PDF)
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S4 Text. Details of imputed genotype data.
(PDF)
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